Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a
Søren Møller, managing partner for seed investments at Novo Holdings, believes successful start-ups in healthcare share a trifecta of component pieces: “great science, the right talent, and
Sales of Novo Nordisk’s fast-growing GLP-1 agonist drugs for diabetes and obesity may be held back by supply constraints, but feverish demand is still driving strong growt
The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’
Earlier this month, pharmaphorum editor-in-chief Jonah Comstock had the opportunity to visit the headquarters of the Novo Nordisk Foundation in Copenhagen, Denmark to talk to several innova
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.